No sex differences were reported for plasma levels of tissue inhibitor metalloproteinase 1 (TIMP-1) (Zhong et al., 2019) and insulin-like growth factor 1 (IGF-1) (Dong et al., 2014; Zhang et al., 2018) 1 day after stroke, matrix metalloproteinase 2 (MMP2) within 2 days after stroke (Montaner et al., 2001), and matrix metalloproteinase 9 (MMP9) 2 days (Montaner et al., 2001; Zhong et al., 2019) and 1 month after stroke (Abdelnaseer et al., 2017). This evidence concerns the gene IGF1 and stroke disorder.